NDAORALTABLET
Approved
May 2009
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
19
Mechanism of Action
unknown. However, the efficacy of iloperidone could be mediated through a combination of dopamine type 2 (D 2 ) and serotonin type 2 (5-HT 2 ) antagonism. Iloperidone forms an active metabolite, P88, that has an in vitro receptor binding profile similar to the parent drug.
Pharmacologic Class:
Atypical Antipsychotic
Indications (1)
Clinical Trials (5)
Evaluation of Efficacy and Safety of Iloperidone for the Treatment of Participants With Uncontrolled Hypertension
Started Sep 2025
240 enrolled
HypertensionUncontrolled Hypertension
Pharmacokinetic Study of VHX-896 and Iloperidone Tablets Under Steady-State Conditions
Started Jul 2024
26 enrolled
SchizophreniaBipolar I Disorder
Safety and Tolerability of Open-Labeled Iloperidone in Adolescents
Started May 2023
100 enrolled
SchizophreniaBipolar I Disorder
A Study to Evaluate Iloperidone for the Treatment of Parkinson's Disease Psychosis
Started Jun 2022
0Parkinson Disease Psychosis
Bioequivalence Study Between VHX-896 Tablets and Iloperidone Tablets in Healthy Volunteers
Started Jun 2021
25 enrolled
Healthy
Loss of Exclusivity
LOE Date
Dec 28, 2031
70 months away
Patent Expiry
Dec 28, 2031
Exclusivity Expiry
Apr 2, 2027